Last update Aug. 6, 2017

索磷布韦

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Usually used in combination with Ledispavir in the treatment of hepatitis C.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (moderately elevated molecular weight, good percentage of protein binding and very short half-life) impedes its passage to breast milk in significant amounts, so although there is disagreement (Thompson 2016), some authors consider that treatment with sofosbuvir, alone or in combination with ledipasvir is not contraindicated during breastfeeding (Spera 2016).


See below the information of these related products:

  • Ledipasvir (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Maternal Hepatitis C Infection (Safe product and/or breastfeeding is the best option.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

索磷布韦 is Sofosbuvir in Chinese.

Is written in other languages:

Group

索磷布韦 belongs to this group or family:

Tradenames

Main tradenames from several countries containing 索磷布韦 in its composition:

  • Epclusa™. Contains other elements than 索磷布韦 in its composition
  • Harvoni™. Contains other elements than 索磷布韦 in its composition
  • Sovaldi™

Pharmacokinetics

Variable Value Unit
Molecular weight 530 daltons
Protein Binding 60 - 85 %
Tmax 0.5 - 2 hours
T½ 0.5 hours

References

  1. Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet. 2019 Oct;58(10):1237-1263. Abstract
  2. EMA. Ledipasvir/Sofosbuvir (Harvoni). Ficha técnica. 2017 Full text (in our servers)
  3. EMA. Ledipasvir/Sofosbuvir (Harvoni). Drug Summary. 2017 Full text (in our servers)
  4. EMA. Sofosbuvir (Sovaldi). Ficha técnica. 2017 Full text (in our servers)
  5. EMA. Sofosbuvir/Velpatasvir (Epclusa). Ficha técnica. 2017 Full text (in our servers)
  6. EMA. Sofosbuvir/Velpatasvir (Epclusa). Drug Summary. 2017 Full text (in our servers)
  7. EMA. Sofosbuvir (Sovaldi). Drug Summary. 2017 Full text (in our servers)
  8. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016 Abstract Full text (link to original source) Full text (in our servers)
  9. Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? World J Hepatol. 2016 Abstract Full text (link to original source) Full text (in our servers)

Total visits

1,697

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM